Antifúngicos: lo que tenemos, lo que tendremos, lo que queremos.

Abstract

It is estimated that 300 million people have some fungal infec-tion, and 1.5 million die annually because of it, similar to the mortality from tuberculosis and three times more than malaria. These numbers may be higher since mycoses are not mandatory reporting. With the lessons learned during the SARS-CoV-19 pandemic, the 2022 outbreak of Monkeypox, the resistance to antibacterial, and the recognition by the WHO that mycoses receive very little attention and resources, added to the fact that available antifungals have significant adverse effects, poor oral bioavailability and growing resistance, it is imperative to develop new antifungals with better pharmacokinetics and phar-macodynamic characteristics, a broad spectrum at affordable costs and world-wide supply. It is what we want. A huge challenge.